[Immune-related pneumonitis: A differential diagnosis of SARS-CoV-2 pneumonia]Article Published on 2022-09-012023-07-10 Journal: Revue des maladies respiratoires [Category] COVID19(2023년), [키워드] Cancer pulmonaire COVID-19 Immune-related adverse events (IrAE) immune-related pneumonitis Immunothérapie Immunotherapy irAE Lung neoplasm Pneumopathie immuno-induite SARS-CoV-2 [DOI] 10.1016/j.rmr.2022.07.001 PMC 바로가기
Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in JapanObservational Study Published on 2022-08-012022-10-05 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome adverse event Against Anti-spike antibody assumed Cancer conducted controls coronavirus coronavirus 2 COVID-19 Efficacy enrolled hospital Immune checkpoint inhibitor Immune checkpoint inhibitors Immune-related adverse event immunogenicity Immunoglobulin incidence interquartile range irAE irAEs Japan lung cancer median age mRNA mRNA vaccine multicenter observational study nine Patient postvaccination predicted primary end point respiratory risk Safety SARS-CoV-2 seroconverted Seven significantly lower the patient treated vaccination vaccination rate vaccine immunogenicity [DOI] 10.1016/j.jtho.2022.05.015 PMC 바로가기 [Article Type] Observational Study
Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study암 환자 치료에서 PD-1 억제제의 사용에 대한 COVID-19 백신 접종의 영향 : 실제 연구Observational Study Published on 2022-03-012022-08-31 Journal: Journal for immunotherapy of cancer [Category] MERS, SARS, 바이오마커, 임상, 진단, [키워드] Adverse adverse event adverse events age All participants Analysis Aside BBIBP-CorV Cancer Chinese hospital Clinical efficacy Common Terminology Criteria Comorbidities Comorbidity conducted conjunction COVID-19 COVID-19 vaccination COVID-19 vaccine criteria defined determine disease disease control Efficacy Efficacy and safety eligible patient enrolled evaluate event female first dose Frequency functional Gender GRADE Grade 1 grade 3 greater immune Immunotherapy Impact implication inhibitor intestinal tract irAE irAEs less liver lung median age median interval metastatic cancer Mild Most patient Most patients multicenter observational study no significant difference no significant differences observational study Participants Patient Patients with cancer PD-1 performance status Propensity score receive receiving recruited reduce reduced reported response response rate screened selected Side effect significant differences Solid statistically status subgroup subgroups the median Therapies therapy Treatment Tumor vaccination Vaccine was used were used [DOI] 10.1136/jitc-2021-004157 PMC 바로가기 [Article Type] Observational Study
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatmentResearch Report Published on 2021-12-232022-10-31 Journal: Cancer immunology, immunotherapy : CII [Category] COVID-19, [키워드] Adverse adverse event adverse events AEs antibody approved Cancer cancer patient Cancer patients clinical cohort study combination treatment coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine dose eight event fatigue first vaccination FIVE follow-up time Frequency Germany grade 3 Immune-checkpoint inhibitors Immunotherapy information inhibitor injection investigated Ipilimumab irAE median Melanoma men Mild moderate pain mRNA-based nivolumab Patient patients patients’ medical records Precaution receiving reported retrieved Safe Seven Side effect Side effects supplementary material the timing therapy treated Treatment vaccination Vaccine was used [DOI] 10.1007/s00262-021-03133-w PMC 바로가기 [Article Type] Research Report
Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancerarticle Published on 2021-03-302024-09-02 Journal: Thoracic Cancer [Category] 대상포진, [키워드] clinical recommendation irAE non‐small cell lung cancer perioperative immunotherapy [DOI] 10.1111/1759-7714.13942 PMC 바로가기 [Article Type] article
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry surveyClinical/Translational Cancer Immunotherapy Published on 2020-10-162022-10-30 Journal: Journal for immunotherapy of cancer [Category] COVID-19, MERS, SARS, [키워드] addressed adverse event affecting age Antiviral Autoimmunity Cancer change changes in Complication COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 symptom CTLA-4 Defense determine diagnosed dose drug enrolled female Follow-up Immunosuppression Immunosuppressive agents Immunosuppressive medication Immunosuppressive treatment Immunotherapy Impact incidence of COVID-19 Infection infection risk inhibitor irAE joints less long-term treatment medication monotherapy New York oncologist pandemic Patient Patients with cancer PD-L1 Prednisone programmed cell death 1 receptor Regulatory Seven T cell the patient treated viral infection women [DOI] 10.1136/jitc-2020-001550 PMC 바로가기 [Article Type] Clinical/Translational Cancer Immunotherapy